ReviewFrontiers in immunology2026
The complex role of IL-37 in cancer pathogenesis: exploring its influence on hallmarks of cancer.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-37 (IL-37) is a cytokine primarily known for its anti-inflammatory properties, but its role in cancer pathogenesis reveals a complex and multifaceted influence. This review explores IL-37's diverse effects on fundamental hallmarks of cancer, such as tumor cell proliferation, invasion, metastasis, and interactions with the immune system. We discuss how IL-37 can modulate these processes in different contexts-sometimes impeding tumor growth and other times facilitating it-depending on factors including the tumor type, stage, and surrounding microenvironment. The dual nature of IL-37's influence underscores its potential as both a therapeutic target and a biomarker for cancer progression, which remain to be validated in prospective clinical studies. By integrating recent findings, this review aims to provide a comprehensive understanding of IL-37's contributions to cancer biology, offering insights into its possible future applications in personalized cancer treatment strategies and enhancing our ability to tailor interventions based on the specific roles of IL-37 in individual cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.